Synergistic Antitumor Activity of Personalized mRNA Neoantigen Vaccines and PD-1/PD-L1 Inhibitor in Solid Tumors
Immunotherapy for cancer now represents a breakthrough in treatment of solid tumors. However, the clinical efficacy of immune checkpoint inhibitors is still limited by insufficient tumor-specific immune activation and multiple immune escape mechanisms. Personalized mRNA vaccines based on neoantigens offer an encouragin...